Resource impact statement

No significant resource impact is anticipated

We do not expect this guidance to have a significant impact on resources; that is, it will be less than £5 million per year in England (or £9,100 per 100,000 population). This is because the population size is small (around 160 people per year in England are estimated to be eligible and less than 50 people are anticipated to have brentuximab vedotin, based on the current usage in the Cancer Drugs Fund).

The list price of brentuximab vedotin has a discount that is commercial in confidence. Any enquiries from NHS organisations about the patient access scheme should be directed to gb.commercial@takeda.com.

This technology is commissioned by NHS England. Providers are NHS hospital trusts.


This page was last updated: 04 October 2017